Amerikanische Gesellschaft für Hirudotherapie

Effect of hirudin on arterialized venous flap survival in rabbits

Research article published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2021)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Speichel-PharmakologieKlinische StudienArzneimittelentwicklungLiu J et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021

Abstract

Arterialized venous flap (AVF) is limited in clinical application because its survival remains inconsistent and its exact survival mechanism is still unclear. Hirudin is an effective thrombin specific inhibitor, which is isolated from the salivary gland secretions of the leech. Our study evaluated the impact of hirudin on the viability of AVFs in rabbits. Thirty-six rabbits were randomly divided into three groups: sham group (physiological perfusion), control group (AVF), and hirudin group (AVF + hirudin). In hirudin group, 20 antithrombin units (ATU) hirudin (2.5 ml) were injected into each flap. In sham group and control group, the same amount of normal saline was injected into each flap. Status of flap survival, water content, vascular perfusion, histopathology, expression of CD34, VEGF, eNOS and HIF-1α were analyzed in each group. Analysis of oxidative stress was performed by measuring the activity of superoxide dismutase (SOD) and malondialdehyde (MDA). Compared with flaps in sham group with physiological perfusion mode, results of survival rate, perfusion status, SOD activity, expression of CD34, VEGF, and eNOS of AVFs in control group were significantly lower, while water content, MDA level and expression of HIF-1α were higher. The flap condition of AVFs injected with hirudin in hirudin group was improved significantly, and the results were similar to sham group. Our findings revealed that hirudin can effectively improve survival of AVF.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsFibrinolytic AgentsGraft SurvivalHirudinsMaleMalondialdehydeOxidative StressRabbitsSuperoxide DismutaseSurgical Flaps

Zusammenfassung

Arterialized venous flap (AVF) is limited in clinical application because its survival remains inconsistent and its exact survival mechanism is still unclear.

Warum dies für die Hirudotherapie relevant ist

Advances understanding of leech salivary bioactive compounds and their therapeutic potential.

Zitation

Effect of hirudin on arterialized venous flap survival in rabbits.

Liu J et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: March 18, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.